Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole

Journal of Clinical Oncology

Volumn 9, Issue 11, 1991, Pages 2027-2035

  Trump, Donald L ^a   Egorin, Merrill J ^b   Forrest, Alan ^b   Willson, James K V ^b   Remick, Scot ^b   Tutsch, Kendra D ^b  

^a DUKE UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIPYRIDAMOLE; FLUOROURACIL;

ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DRUG INTERACTION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; STOMATITIS;

BONE MARROW DISEASES; DIPYRIDAMOLE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FLUOROURACIL; HUMAN; INFUSIONS, INTRAVENOUS; LEUKOCYTE COUNT; MATHEMATICAL COMPUTING; STOMATITIS; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0026079516     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1991.9.11.2027     Document Type: Article

References (36)

1. Myers CE, Diasio R, Eliot HM, et al: Pharmacokinetics of fluoropyrimidines: Implications for their clinical use. Cancer Treat Rev 3:175-183, 1976
2. Seifert P, Baker LH, Reed M, et al: Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 36:123-128, 1975
3. Fraile RJ, Baker LH, Buroker TR, et al: Pharmacokinetics of 5-fluorouracil administered orally by rapid intravenous and by slow infusion. Cancer Res 40:2223-2228, 1980
4. Spicer DV, Ardalan B, Daniels JR, et al: Reevaluation of the maximum tolerated dose of continuous venous infusion of 5-fluorouracil with pharmacokinetics. Cancer Res 48:459-461, 1988
5. Au JL-S, Rustum YM, Ledesma EJ, et al: Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in treatment of colorectal cancer. Cancer Res 42:2930-2937, 1982
6. Thyss A, Milano G, Renee N, et al: Clinical and pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer. Cancer Chemother Pharmacol 16:64-66, 1986
7. Santini J, Milano G, Thyss A, et al: 5FU therapeutic monitoring with dose adjustment leads to improved therapeutic index in head and neck cancer. Br J Cancer 59:287-290, 1989
8. van Groeningen CJ, Pinedo HM, Heddes J, et al: Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule. Cancer Res 48:6956-6961, 1988
9. Hillcoat BL, McCullouch PB, Figueredo AT, et al: Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion. Br J Cancer 38:719-724, 1978
10. Remick SC, Grem JL, Fischer PF, et al: A phase I trial of 5-fluorouracil (FUra) and dipyridamole administered by 72-hour concurrent continuous infusion. Cancer Res 50:2667-2672, 1990
11. Willson JKV, Fischer PH, Tutsch K, et al: Phase I trial of a combination of dipyridamole and acivicin based upon inhibition of nucleoside salvage. Cancer Res 48:5585-5590, 1988
12. Fischer PF, Willson JKV, Risueno C, et al: Biochemical assessment of the effects of acivicin and dipyridamole given as a continuous 72-hour intravenous infusion. Cancer Res 48:5591-5596, 1988
13. Willson JKV, Fischer PF, Remick SC, et al: Methotrexate and dipyridamole combination of chemotherapy based on inhibition of nucleoside salvage in humans. Cancer Res 49:1866-1870, 1989
14. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
15. Stetson PL, Shukla UA, Ensminger WD: Sensitive high-performance liquid chromatographic method for the determination of 5-fluorouracil in plasma. J Chromatogr Biomed Appl 344:385-390, 1985
16. D'Argenio DZ, Schumitzky AA: A program for simulation and parameter estimation in pharmacokinetic systems. Comput Methods Programs Biomed 9:115-134, 1979
17. Wagner JG: Kinetics of pharmacologic response. I. Proposed relationships between response and drug concentration in intact animal and man. J Theor Biol 20:171-201, 1968
18. Akakie HA: A Bayesian extension of the minimal AIC procedures of autoregressive model fitting. Biometrika 66:237-242, 1979
19. Galeazzi RL, Benet LZ, Scheiner LB: Relationship between the pharmacokinetics and pharmacodynamics of procainamide. Clin Pharmacol Ther 20:278-289, 1976
20. Zhou HH, Koshakji RP, Silberstein DJ, et al: Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. N Engl J Med 320:565-570, 1989
21. Koch-Weser J: Serum drug concentrations as therapeutic guides. N Engl J Med 287:227-231, 1972
22. Stoller RG, Hande KR, Jacobs SA, et al: Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med 297:630-634, 1977
23. Egorin MJ, Sigman LM, Van Echo DA, et al: Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion. Cancer Res 47:617-623, 1987
24. Egorin MJ, Van Echo D, Tipping SJ, et al: Pharmacokinetics and dosage reduction of cis-daimmine (1,1-cyclobutanedicarboxylato) platinum in patients with impaired renal function. Cancer Res 44:5432-5438, 1984
25. Egorin MJ, Van Echo DA, Olman EA, et al: Prospecfive validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum (II) analogue diammine cyclobutane dicarboxylatoplatinum. Cancer Res 45: 6502-6506, 1985
26. Bennett CL, Sinkule JA, Schilsky RL, et al: Phase I clinical and pharmacologic study of seventy-two-hour continuous infusion of etoposide in patients with advanced cancer. Cancer Res 47:1952-1956, 1987
27. Egorin MJ, Van Echo DA, Whitacre MY, et al: Human pharmacokinetics, excretion and metabolism of the anthracycline antibiotic (7-OMEN, NSC 269148) and their correlation with clinical toxicities. Cancer Res 46:1513-1520, 1986
28. Evans WE, Crom WR, Abromowitch M, et al: Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. N Engl J Med 314:471-477, 1986
29. Rodman JH, Abromowitch M, Sinkule JA, et al: Clinical pharmacodynamics of continuous infusion teniposide: Systemic exposure as a determinant of response in a phase I trial. J Clin Oncol 5:1007-1014, 1987
30. Horton J, Olson KB, Sullivan J, et al: 5-Fluorouracil in cancer: An improved regimen. Ann Intern Med 78:897-900, 1970
31. Ansfield F, Klotz J, Nealon T, et al: A phase III study comparing the clinical utility of four regimens of 5-fluorouracil. A preliminary report. Cancer 39:34-40, 1977
32. Hahn RG, Moertel CG, Schutt AJ, et al: A double blind comparison of intensive course 5-fluorouracil by oral v intravenous route in the treatment of colorectal carcinoma. Cancer 35:1031-1035, 1975
33. Hryniuk WM, Figueredo A, Goodyear M: Applications of dose intensity analysis to problems in chemotherapy of breast and colorectal cancer. Semin Oncol 14:3-11, 1987
34. Shah A, MacDonald W, Goldie J, et al: 5FU infusion in advanced colorectal cancer: A comparison of three dose schedules. Cancer Treat Rep 69:739-742, 1985
35. Grem JL, Fischer PH: Alteration of fluorouracil metabolism in human colon cancer cells by dipyridamole with a selective increase in fluorodeoxyuridine monophosphate levels. Cancer Res 46:6191-6199, 1986
36. Grem JL, Fischer PH: Enhancement of 5-fluorouracil's activity by dipyridamole. Pharmacol Ther 40:349-371, 1989